Ken Griffin Corcept Therapeutics Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$29.51 - $46.26 $1.41 Million - $2.21 Million	-47,700 Reduced 25.66%	138,200 $6.39 Million
Q2 2024 Aug 14, 2024	SELL	$22.21 - $34.48 $2.01 Million - $3.12 Million	-90,600 Reduced 32.77%	185,900 $6.04 Million
Q1 2024 May 15, 2024	BUY	$21.1 - $27.46 $4.06 Million - $5.28 Million	192,400 Added 228.78%	276,500 $6.97 Million
Q4 2023 Feb 14, 2024	BUY	$24.82 - $32.88 $1.19 Million - $1.57 Million	47,900 Added 132.32%	84,100 $2.73 Million
Q3 2023 Nov 14, 2023	BUY	$21.97 - $33.8 $551,447 - $848,379	25,100 Added 226.13%	36,200 $986,000
Q2 2023 Aug 14, 2023	SELL	$21.44 - $25.15 $240,128 - $281,680	-11,200 Reduced 50.22%	11,100 $246,000
Q1 2023 May 15, 2023	SELL	$19.2 - $24.47 $656,640 - $836,874	-34,200 Reduced 60.53%	22,300 $483,000
Q4 2022 Feb 14, 2023	BUY	$19.95 - $29.96 $259,350 - $389,480	13,000 Added 29.89%	56,500 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $612,560 - $722,176	24,800 Added 132.62%	43,500 $1.12 Million

346

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.59B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.